Association of aspirin use with major bleeding in patients with and without diabetes.
Abstract
CONTEXT
The benefit of aspirin for the primary prevention of cardiovascular events is relatively small for individuals with and without
diabetes. This benefit could easily be offset by the risk of hemorrhage.
OBJECTIVE
To determine the incidence of major gastrointestinal and intracranial bleeding episodes in individuals with and without diabetes
taking aspirin.
DESIGN, SETTING, AND PARTICIPANTS
A population-based cohort study, using administrative data from 4.1 million citizens in 12 local health authorities in Puglia,
Italy. Individuals with new prescriptions for low-dose aspirin (≤300 mg) were identified during the index period from January
1, 2003, to December 31, 2008, and were propensity-matched on a 1-to-1 basis with individuals who did not take aspirin during
this period.
MAIN OUTCOME MEASURES
Hospitalizations for major gastrointestinal bleeding or cerebral hemorrhage occurring after the initiation of antiplatelet
therapy.
RESULTS
There were 186,425 individuals being treated with low-dose aspirin and 186,425 matched controls without aspirin use. During
a median follow-up of 5.7 years, the overall incidence rate of hemorrhagic events was 5.58 (95% CI, 5.39-5.77) per 1000 person-years
for aspirin users and 3.60 (95% CI, 3.48-3.72) per 1000 person-years for those without aspirin use (incidence rate ratio [IRR],
1.55; 95% CI, 1.48-1.63). The use of aspirin was associated with a greater risk of major bleeding in most of the subgroups
investigated but not in individuals with diabetes (IRR, 1.09; 95% CI, 0.97-1.22). Irrespective of aspirin use, diabetes was
independently associated with an increased risk of major bleeding episodes (IRR, 1.36; 95% CI, 1.28-1.44).
CONCLUSIONS
In a population-based cohort, aspirin use was significantly associated with an increased risk of major gastrointestinal or
cerebral bleeding episodes. Patients with diabetes had a high rate of bleeding that was not independently associated with
aspirin use.
Links
Authors
De Berardis G, Lucisano G, D'Ettorre A, Pellegrini F, Lepore V, Tognoni G, Nicolucci A
Institution
Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy.
Source
JAMA : the journal of the American Medical Association 307:21 2012 Jun 6 pg 2286-94MeSH
AdultAged
Aged, 80 and over
Aspirin
Cardiovascular Diseases
Case-Control Studies
Cohort Studies
Diabetes Mellitus
Female
Gastrointestinal Hemorrhage
Humans
Incidence
Intracranial Hemorrhages
Italy
Male
Middle Aged
Platelet Aggregation Inhibitors
Risk
Pub Type(s)
Journal ArticleLanguage
eng
PubMed ID
22706834
Log In

